Spider-venom peptides as therapeutics

Toxins

Volumn 2, Issue 12, 2010, Pages 2851-2871

  Saez, Natalie J ^a   Senff, Sebastian ^a   Jensen, Jonas E ^a   Er, Sing Yan ^a   Herzig, Volker ^a   Rash, Lachlan D ^a   King, Glenn F ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Cystine knot; Drug discovery; Drugs; Peptide; Spider venom; Therapeutics

Indexed keywords

5 [[(3 PHENOXYBENZYL)(1,2,3,4 TETRAHYDRO 1 NAPHTHYL)AMINO]CARBONYL]TRIMELLITIC ACID; ACID SENSING ION CHANNEL; ANALGESIC AGENT; ANTIARRHYTHMIC AGENT; ANTIBACTERIAL TOXIN; ANTIFUNGAL TOXIN; CALCIUM CHANNEL BLOCKING AGENT; CYSTEINE; DELTA CTENITOXIN PN2A; INHIBITOR CYSTINE KNOT; M THERAPHOTOXIN GR1A; MORPHINE; OMEGA CONOTOXIN MVIIA; PEPTIDE; PHRIXOTOXIN 2; PI THERAPHOTOXIN PC1A; PSALMOPEOTOXIN 1; PSALMOPEOTOXIN 2; PSALMOTOXIN 1; PURINERGIC P2X RECEPTOR; PUROTOXIN 1; SODIUM CHANNEL BLOCKING AGENT; SODIUM CHANNEL NAV1.7; SPIDER VENOM; TETRODOTOXIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANILLOID RECEPTOR 1; VANILLOID RECEPTOR 1 ANTAGONIST; VANILLOID RECEPTOR 4; VOLTAGE GATED SODIUM CHANNEL;

AMINO TERMINAL SEQUENCE; ANALGESIC ACTIVITY; ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; BRAIN ISCHEMIA; CHRONIC PAIN; DRUG ACTIVITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG STABILITY; ERECTILE DYSFUNCTION; GENE FUNCTION; GENE MUTATION; HUMAN; IC 50; NEUROPROTECTION; NONHUMAN; PAIN; PROTEIN MOTIF; REVIEW;

ANALGESICS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; ANTIMALARIALS; CYSTINE KNOT MOTIFS; ERECTILE DYSFUNCTION; HUMANS; MALE; PEPTIDES; SPIDER VENOMS;

ANIMALIA; ARANEAE;

EID: 79952075874     PISSN: None     EISSN: 20726651     Source Type: Journal    
DOI: 10.3390/toxins2122851     Document Type: Review

References (136)

1. Coddington, J.A.; Levi, H.W. Systematics and evolution of spiders (Araneae). Annu. Rev. Ecol. Syst. 1991, 22, 565-592.
2. Isbister, G.K.; White, J. Clinical consequences of spider bite: recent advances in our understanding. Toxicon 2004, 43, 477-492.
3. King, G.F. The wonderful world of spiders: preface to the special Toxicon issue on spider venoms. Toxicon 2004, 43, 471-476.
4. Escoubas, P.; Diochot, S.; Corzo, G. Structure and pharmacology of spider venom neurotoxins. Biochimie 2000, 82, 893-907.
5. Rash, L.D.; Hodgson, W.C. Pharmacology and biochemistry of spider venoms. Toxicon 2002, 40, 225-254.
6. Tedford, H.W.; Sollod, B.L.; Maggio, F.; King, G.F. Australian funnel-web spiders: Master insecticide chemists. Toxicon 2004, 43, 601-618.
7. Escoubas, P.; Rash, L. Tarantulas: Eight-legged pharmacists and combinatorial chemists. Toxicon 2004, 43, 555-574.
8. Estrada, G.; Villegas, E.; Corzo, G. Spider venoms: a rich source of acylpolyamines and peptides as new leads for CNS drugs. Nat. Prod. Rep. 2007, 24, 145-161.
9. Vassilevski, A.A.; Kozlov, S.A.; Grishin, E.V. Molecular diversity of spider venom. Biochemistry 2009, 74, 1505-1534.
10. Escoubas, P.; Sollod, B.; King, G.F. Venom landscapes: mining the complexity of spider venoms via a combined cDNA and mass spectrometric approach. Toxicon 2006, 47, 650-663.
11. Escoubas, P.; King, G.F. Venomics as a drug discovery platform. Expert Rev. Proteomics 2009, 6, 221-224.
12. King, G.F.; Gentz, M.C.; Escoubas, P.; Nicholson, G.M. A rational nomenclature for naming peptide toxins from spiders and other venomous animals. Toxicon 2008, 52, 264-276.
13. Liao, Z.; Cao, J.; Li, S.; Yan, X.; Hu, W.; He, Q.; Chen, J.; Tang, J.; Xie, J.; Liang, S. Proteomic and peptidomic analysis of the venom from Chinese tarantula Chilobrachys jingzhao. Proteomics 2007, 7, 1892-1907.
14. Richardson, M.; Pimenta, A.M.; Bemquerer, M.P.; Santoro, M.M.; Beirao, P.S.; Lima, M.E.; Figueiredo, S.G.; Bloch, C., Jr.; Vasconcelos, E.A.; Campos, F.A.; Gomes, P.C.; Cordeiro, M.N. Comparison of the partial proteomes of the venoms of Brazilian spiders of the genus Phoneutria. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 2006, 142, 173-187.
15. de F Fernandes-Pedrosa, M.; de LM Junqueira-de-Azevedo, I.; Gonçalves-de-Andrade, R.M.; Kobashi, L.S.; Almeida, D.D.; Ho, P.L.; Tambourgi, D.V. Transcriptome analysis of Loxosceles laeta (Araneae, Sicariidae) spider venomous gland using expressed sequence tags. BMC Genomics 2008, 9, 279.
16. Jiang, L.; Peng, L.; Chen, J.; Zhang, Y.; Xiong, X.; Liang, S. Molecular diversification based on analysis of expressed sequence tags from the venom glands of the Chinese bird spider Ornithoctonus huwena. Toxicon 2008, 51, 1479-1489.
17. Kozlov, S.; Malyavka, A.; McCutchen, B.; Lu, A.; Schepers, E.; Herrmann, R.; Grishin, E. A novel strategy for the identification of toxinlike structures in spider venom. Proteins 2005, 59, 131-140.
18. Diego-Garcia, E.; Peigneur, S.; Waelkens, E.; Debaveye, S.; Tytgat, J. Venom components from Citharischius crawshayi spider (Family Theraphosidae): Exploring transcriptome, venomics, and function. Cell. Mol. Life Sci. 2010, 67, 2799-2813.
19. Tang, X.; Zhang, Y.; Hu, W.; Xu, D.; Tao, H.; Yang, X.; Li, Y.; Jiang, L.; Liang, S. Molecular diversification of peptide toxins from the tarantula Haplopelma hainanum (Ornithoctonus hainana) venom based on transcriptomic, peptidomic, and genomic analyses. J. Proteome Res. 2010, 9, 2550-2564.
20. Wood, D.L.; Miljenovic, T.; Cai, S.; Raven, R.J.; Kaas, Q.; Escoubas, P.; Herzig, V.; Wilson, D.; King, G.F. ArachnoServer: A database of protein toxins from spiders. BMC Genomics 2009, 10, 375.
21. Herzig, V.; Wood, D.L.A.; Newell, F.; Chaumeil, P.-A.; Kaas, Q.; Binford, G.J.; Nicholson, G.M.; Gorse, D.; King, G.F. ArachnoServer 2.0, an updated online resource for spider toxin sequences and structures. Nucl. Acids Res. 2010, doi:10.1093/nar/gkq1058.
22. Gao, L.; Shan, B.E.; Chen, J.; Liu, J.H.; Song, D.X.; Zhu, B.C. Effects of spider Macrothele raven venom on cell proliferation and cytotoxicity in HeLa cells. Acta Pharmacol. Sin. 2005, 26, 369-376.
23. Gao, L.; Yu, S.; Wu, Y.; Shan, B. Effect of spider venom on cell apoptosis and necrosis rates in MCF-7 cells. DNA Cell Biol. 2007, 26, 485-489.
24. Ushkaryov, Y.A.; Volynski, K.E.; Ashton, A.C. The multiple actions of black widow spider toxins and their selective use in neurosecretion studies. Toxicon 2004, 43, 527-542.
25. Swartz, K.J.; MacKinnon, R. An inhibitor of the Kv2.1 potassium channel isolated from the venom of a Chilean tarantula. Neuron 1995, 15, 941-949.
26. Adams, M.E. Agatoxins: Ion channel specific toxins from the American funnel web spider, Agelenopsis aperta. Toxicon 2004, 43, 509-525.
27. King, G.F. Modulation of insect CaV channels by peptidic spider toxins. Toxicon 2007, 49, 513-530.
28. King, G.F.; Escoubas, P.; Nicholson, G.M. Peptide toxins that selectively target insect NaV and CaV channels. Channels 2008, 2, 100-116.
29. Grishin, E.V.; Savchenko, G.A.; Vassilevski, A.A.; Korolkova, Y.V.; Boychuk, Y.A.; Viatchenko-Karpinski, V.Y.; Nadezhdin, K.D.; Arseniev, A.S.; Pluzhnikov, K.A.; Kulyk, V.B.; Voitenko, N.V.; Krishtal, O.O. Novel peptide from spider venom inhibits P2X3 receptors and inflammatory pain. Ann. Neurol. 2010, 67, 680-683.
30. Escoubas, P.; De Weille, J.R.; Lecoq, A.; Diochot, S.; Waldmann, R.; Champigny, G.; Moinier, D.; Menez, A.; Lazdunski, M. Isolation of a tarantula toxin specific for a class of proton-gated Na+ channels. J. Biol. Chem. 2000, 275, 25116-25121.
31. Bowman, C.L.; Gottlieb, P.A.; Suchyna, T.M.; Murphy, Y.K.; Sachs, F. Mechanosensitive ion channels and the peptide inhibitor GsMTx-4: history, properties, mechanisms and pharmacology. Toxicon 2007, 49, 249-270.
32. Siemens, J.; Zhou, S.; Piskorowski, R.; Nikai, T.; Lumpkin, E.A.; Basbaum, A.I.; King, D.; Julius, D. Spider toxins activate the capsaicin receptor to produce inflammatory pain. Nature 2006, 444, 208-212.
33. Escoubas, P.; Bosmans, F. Spider peptide toxins as leads for drug development. Expert Opin. Drug Discov. 2007, 2, 823-835.
34. Walker, M.J.A.; Barrett, T.; Guppy, L.J. Functional pharmacology: The drug discovery bottleneck? Drug Discov. Today 2004, 3, 208-215.
35. Billingsley, M.L. Druggable targets and targeted drugs: enhancing the development of new therapeutics. Pharmacology 2008, 82, 239-244.
36. Vetter, I.; Davis, J.L.; Rash, L.D.; Anangi, R.; Mobli, M.; Alewood, P.F.; Lewis, R.J.; King, G.F. Venomics: a new paradigm for natural products-based drug discovery. Amino Acids 2010, doi:10.1007/s00726-00010-00516-00724.
37. Nestor, J.J., Jr. The medicinal chemistry of peptides. Curr. Med. Chem. 2009, 16, 4399-4418.
38. Hamman, J.H.; Enslin, G.M.; Kotze, A.F. Oral delivery of peptide drugs: Barriers and developments. BioDrugs 2005, 19, 165-177.
39. Pallaghy, P.K.; Nielsen, K.J.; Craik, D.J.; Norton, R.S. A common structural motif incorporating a cystine knot and a triple-stranded β-sheet in toxic and inhibitory polypeptides. Protein Sci. 1994, 3, 1833-1839.
40. Norton, R.S.; Pallaghy, P.K. The cystine knot structure of ion channel toxins and related polypeptides. Toxicon 1998, 36, 1573-1583.
41. King, G.F.; Tedford, H.W.; Maggio, F. Structure and function of insecticidal neurotoxins from Australian funnel-web spiders. J. Toxicol. Toxin Rev. 2002, 21, 359-389.
42. Fletcher, J.I.; Chapman, B.E.; Mackay, J.P.; Howden, M.E.H.; King, G.F. The structure of versutoxin (δ-atracotoxin-Hv1) provides insights into the binding of site 3 neurotoxins to the voltage-gated sodium channel. Structure 1997, 5, 1525-1535.
43. Fletcher, J.I.; Smith, R.; O'Donoghue, S.I.; Nilges, M.; Connor, M.; Howden, M.E.H.; Christie, M.J.; King, G.F. The structure of a novel insecticidal neurotoxin, ω-atracotoxin-HV1, from the venom of an Australian funnel web spider. Nat. Struct. Biol. 1997, 4, 559-566.
44. Craik, D.J.; Daly, N.L.; Waine, C. The cystine knot motif in toxins and implications for drug design. Toxicon 2001, 39, 43-60.
45. Colgrave, M.L.; Craik, D.J. Thermal, chemical, and enzymatic stability of the cyclotide kalata B1: The importance of the cyclic cystine knot. Biochemistry 2004, 43, 5965-5975.
46. Fu, T.J.; Abbott, U.R.; Hatzos, C. Digestibility of food allergens and nonallergenic proteins in simulated gastric fluid and simulated intestinal fluid-A comparative study. J. Agric. Food Chem. 2002, 50, 7154-7160.
47. Clark, R.J.; Jensen, J.; Nevin, S.T.; Callaghan, B.P.; Adams, D.J.; Craik, D.J. The engineering of an orally active conotoxin for the treatment of neuropathic pain. Angew. Chem. Int. Ed. 2010, 49, 6545-6548.
48. Sollod, B.L.; Wilson, D.; Zhaxybayeva, O.; Gogarten, J.P.; Drinkwater, R.; King, G.F. Were arachnids the first to use combinatorial peptide libraries? Peptides 2005, 26, 131-139.
49. Brennan, F.; Carr, D.B.; Cousins, M. Pain management: A fundamental human right. Anesth. Analg. 2007, 105, 205-221.
50. The global pain market, 2008-2023; Visiongain ltd.: London, UK, 2008.
51. Kellenberger, S.; Schild, L. Epithelial sodium channel/degenerin family of ion channels: A variety of functions for a shared structure. Physiol. Rev. 2002, 82, 735-767.
52. Lingueglia, E. Acid-sensing ion channels in sensory perception. J. Biol. Chem. 2007, 282, 17325-17329.
53. Gründer, S.; Chen, X. Structure, function, and pharmacology of acid-sensing ion channels (ASICs): Focus on ASIC1a. Int. J. Physiol. Pathophysiol. Pharmacol. 2010, 2, 73-94.
54. Wemmie, J.A.; Price, M.P.; Welsh, M.J. Acid-sensing ion channels: Advances, questions and therapeutic opportunities. Trends Neurosci. 2006, 29, 578-586.
55. Xiong, Z.G.; Pignataro, G.; Li, M.; Chang, S.Y.; Simon, R.P. Acid-sensing ion channels (ASICs) as pharmacological targets for neurodegenerative diseases. Curr. Opin. Pharmacol. 2008, 8, 25-32.
56. Sluka, K.A.; Winter, O.C.; Wemmie, J.A. Acid-sensing ion channels: a new target for pain and CNS diseases. Curr. Opin. Drug Discov. Devel. 2009, 12, 693-704.
57. Mazzuca, M.; Heurteaux, C.; Alloui, A.; Diochot, S.; Baron, A.; Voilley, N.; Blondeau, N.; Escoubas, P.; Gelot, A.; Cupo, A.; Zimmer, A.; Zimmer, A.M.; Eschalier, A.; Lazdunski, M. A tarantula peptide against pain via ASIC1a channels and opioid mechanisms. Nat. Neurosci. 2007, 10, 943-945.
58. Pignataro, G.; Simon, R.P.; Xiong, Z.G. Prolonged activation of ASIC1a and the time window for neuroprotection in cerebral ischaemia. Brain 2007, 130, 151-158.
59. Smith, H.S.; Deer, T.R.; Staats, P.S.; Singh, V.; Sehgal, N.; Cordner, H. Intrathecal drug delivery. Pain Physician 2008, 11, S89-S104.
60. Kress, H.G.; Simpson, K.H.; Marchettini, P.; Ver Donck, A.; Varrassi, G. Intrathecal therapy: what has changed with the introduction of ziconotide. Pain Pract. 2009, 9, 338-347.
61. Qadri, Y.J.; Berdiev, B.K.; Song, Y.; Lippton, H.L.; Fuller, C.M.; Benos, D.J. Psalmotoxin-1 docking to human acid-sensing ion channel-1. J. Biol. Chem. 2009, 284, 17625-17633.
62. Pietra, F. Docking and MD simulations of the interaction of the tarantula peptide psalmotoxin-1 with ASIC1a channels using a homology model. J. Chem. Inf. Model. 2009, 49, 972-977.
63. Yu, F.H.; Catterall, W.A. Overview of the voltage-gated sodium channel family. Genome Biol. 2003, 4, 207.
64. Krafte, D.S.; Bannon, A.W. Sodium channels and nociception: Recent concepts and therapeutic opportunities. Current Opin. Pharmacol. 2008, 8, 50-56.
65. Priest, B.T. Future potential and status of selective sodium channel blockers for the treatment of pain. Curr. Opin. Drug Discov. Devel. 2009, 12, 682-692.
66. Yang, Y.; Wang, Y.; Li, S.; Xu, Z.; Li, H.; Ma, L.; Fan, J.; Bu, D.; Liu, B.; Fan, Z.; Wu, G.; Jin, J.; Ding, B.; Zhu, X.; Shen, Y. Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J. Med. Genet. 2004, 41, 171-174.
67. Fertleman, C.R.; Baker, M.D.; Parker, K.A.; Moffatt, S.; Elmslie, F.V.; Abrahamsen, B.; Ostman, J.; Klugbauer, N.; Wood, J.N.; Gardiner, R.M.; Rees, M. SCN9A mutations in paroxysmal extreme pain disorder: Allelic variants underlie distinct channel defects and phenotypes. Neuron 2006, 52, 767-774.
68. Cox, J.J.; Reimann, F.; Nicholas, A.K.; Thornton, G.; Roberts, E.; Springell, K.; Karbani, G.; Jafri, H.; Mannan, J.; Raashid, Y.; Al-Gazali, L.; Hamamy, H.; Valente, E.M.; Gorman, S.; Williams, R.; McHale, D.P.; Wood, J.N.; Gribble, F.M.; Woods, C.G. An SCN9A channelopathy causes congenital inability to experience pain. Nature 2006, 444, 894-898.
69. Goldberg, Y.P.; MacFarlane, J.; MacDonald, M.L.; Thompson, J.; Dube, M.P.; Mattice, M.; Fraser, R.; Young, C.; Hossain, S.; Pape, T.; Payne, B.; Radomski, C.; Donaldson, G.; Ives, E.; Cox, J.; Younghusband, H.B.; Green, R.; Duff, A.; Boltshauser, E.; Grinspan, G.A.; Dimon, J.H.; Sibley, B.G.; Andria, G.; Toscano, E.; Kerdraon, J.; Bowsher, D.; Pimstone, S.N.; Samuels, M.E.; Sherrington, R.; Hayden, M.R. Loss-of-function mutations in the NaV1.7 gene underlie congenital indifference to pain in multiple human populations. Clin. Genet. 2007, 71, 311-319.
70. Nilsen, K.B.; Nicholas, A.K.; Woods, C.G.; Mellgren, S.I.; Nebuchennykh, M.; Aasly, J. Two novel SCN9A mutations causing insensitivity to pain. Pain 2009, 143, 155-158.
71. Clare, J.J. Targeting voltage-gated sodium channels for pain therapy. Expert Opin. Invest. Drugs 2010, 19, 45-62.
72. Maggio, F.; Sollod, B.L.; Tedford, H.W.; Herzig, V.; King, G.F. Spider toxins and their potential for insect control. In Insect Pharmacology: Channels, Receptors, Toxins and Enzymes; Gilbert, L.I.; Gill, S.S., Eds.; Academic Press: London, UK, 2010; pp. 101-123.
73. Middleton, R.E.; Warren, V.A.; Kraus, R.L.; Hwang, J.C.; Liu, C.J.; Dai, G.; Brochu, R.M.; Kohler, M.G.; Gao, Y.D.; Garsky, V.M.; Bogusky, M.J.; Mehl, J.T.; Cohen, C.J.; Smith, M.M. Two tarantula peptides inhibit activation of multiple sodium channels. Biochemistry 2002, 41, 14734-14747.
74. Schmalhofer, W.A.; Calhoun, J.; Burrows, R.; Bailey, T.; Kohler, M.G.; Weinglass, A.B.; Kaczorowski, G.J.; Garcia, M.L.; Koltzenburg, M.; Priest, B.T. ProTx-II, a selective inhibitor of NaV1.7 sodium channels, blocks action potential propagation in nociceptors. Mol. Pharmacol. 2008, 74, 1476-1484.
75. Lampe, R.A. Analgesic peptides from the venom of Grammostola spatulata. U.S. Patent 5,877,026, 2 March 1999.
76. Khakh, B.S.; North, R.A. P2X receptors as cell-surface ATP sensors in health and disease. Nature 2006, 442, 527-532.
77. Skaper, S.D.; Debetto, P.; Giusti, P. The P2X7 purinergic receptor: from physiology to neurological disorders. FASEB J. 2010, 24, 337-345.
78. Nicke, A.; Baumert, H.G.; Rettinger, J.; Eichele, A.; Lambrecht, G.; Mutschler, E.; Schmalzing, G. P2X1 and P2X3 receptors form stable trimers: a novel structural motif of ligand-gated ion channels. EMBO J. 1998, 17, 3016-3028
79. Wirkner, K.; Sperlagh, B.; Illes, P. P2X3 receptor involvement in pain states. Mol. Neurobiol. 2007, 36, 165-183.
80. Tsuda, M.; Shigemoto-Mogami, Y.; Koizumi, S.; Mizokoshi, A.; Kohsaka, S.; Salter, M.W.; Inoue, K. P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. Nature 2003, 424, 778-783.
81. Gunosewoyo, H.; Kassiou, M. P2X purinergic receptor ligands: recently patented compounds. Expert Opin. Ther. Pat. 2010, 20, 625-646.
82. North, R.A. P2X3 receptors and peripheral pain mechanisms. J. Physiol. 2004, 554, 301-308.
83. Jarvis, M.F.; Burgard, E.C.; McGaraughty, S.; Honore, P.; Lynch, K.; Brennan, T.J.; Subieta, A.; Van Biesen, T.; Cartmell, J.; Bianchi, B.; Niforatos, W.; Kage, K.; Yu, H.; Mikusa, J.; Wismer, C.T.; Zhu, C.Z.; Chu, K.; Lee, C.H.; Stewart, A.O.; Polakowski, J.; Cox, B.F.; Kowaluk, E.; Williams, M.; Sullivan, J.; Faltynek, C. A-317491, a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat. Proc. Natl. Acad. Sci. USA 2002, 99, 17179-17184.
84. Hausmann, R.; Rettinger, J.; Gerevich, Z.; Meis, S.; Kassack, M.U.; Illes, P.; Lambrecht, G.; Schmalzing, G. The suramin analog 4,4',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis (carbonylimino)))tetra-kis-benzenesulfonic acid (NF110) potently blocks P2X3 receptors: Subtype selectivity is determined by location of sulfonic acid groups. Mol. Pharmacol. 2006, 69, 2058-2067.
85. Jung, K.Y.; Moon, H.D.; Lee, G.E.; Lim, H.H.; Park, C.S.; Kim, Y.C. Structure-activity relationship studies of spinorphin as a potent and selective human P2X(3) receptor antagonist. J. Med. Chem. 2007, 50, 4543-4547.
86. Miljanich, G.P. Ziconotide: neuronal calcium channel blocker for treating severe chronic pain. Curr. Med. Chem. 2004, 11, 3029-3040.
87. Sharpe, I.A.; Gehrmann, J.; Loughnan, M.L.; Thomas, L.; Adams, D.A.; Atkins, A.; Palant, E.; Craik, D.J.; Adams, D.J.; Alewood, P.F.; Lewis, R.J. Two new classes of conopeptides inhibit the α1-adrenoceptor and noradrenaline transporter. Nat. Neurosci. 2001, 4, 902-907.
88. Patapoutian, A.; Tate, S.; Woolf, C.J. Transient receptor potential channels: Targeting pain at the source. Nat. Rev. Drug Discov. 2009, 8, 55-68.
89. Cortright, D.N.; Szallasi, A. TRP channels and pain. Curr. Pharm. Des. 2009, 15, 1736-1749.
90. Martinac, B.; Kloda, A. Evolutionary origins of mechanosensitive ion channels. Prog. Biophys. Mol. Biol. 2003, 82, 11-24.
91. Sachs, F. Stretch-activated ion channels: What are they? Physiology 2010, 25, 50-56.
92. Suchyna, T.M.; Johnson, J.H.; Hamer, K.; Leykam, J.F.; Gage, D.A.; Clemo, H.F.; Baumgarten, C.M.; Sachs, F. Identification of a peptide toxin from Grammostola spatulata spider venom that blocks cation-selective stretch-activated channels. J. Gen. Physiol. 2000, 115, 583-598.
93. Oswald, R.E.; Suchyna, T.M.; McFeeters, R.; Gottlieb, P.; Sachs, F. Solution structure of peptide toxins that block mechanosensitive ion channels. J. Biol. Chem. 2002, 277, 34443-34450.
94. Bode, F.; Sachs, F.; Franz, M.R. Tarantula peptide inhibits atrial fibrillation. Nature 2001, 409, 35-36.
95. Suchyna, T.M.; Tape, S.E.; Koeppe, R.E., 2nd; Andersen, O.S.; Sachs, F.; Gottlieb, P.A. Bilayer-dependent inhibition of mechanosensitive channels by neuroactive peptide enantiomers. Nature 2004, 430, 235-240.
96. Garcia, M.L. Ion channels: Gate expectations. Nature 2004, 430, 153-155.
97. Jung, H.J.; Kim, P.I.; Lee, S.K.; Lee, C.W.; Eu, Y.J.; Lee, D.G.; Earm, Y.E.; Kim, J.I. Lipid membrane interaction and antimicrobial activity of GsMTx-4, an inhibitor of mechanosensitive channel. Biochem. Biophys. Res. Commun. 2006, 340, 633-638.
98. Andersson, K.E.; Wagner, G. Physiology of penile erection. Physiol. Rev. 1995, 75, 191-236.
99. Toda, N.; Ayajiki, K.; Okamura, T. Nitric oxide and penile erectile function. Pharmacol. Therapeut. 2005, 106, 233-266.
100. Fusco, F.; Razzoli, E.; Imbimbo, C.; Rossi, A.; Verze, P.; Mirone, V. A new era in the treatment of erectile dysfunction: Chronic phosphodiesterase type 5 inhibition. BJU Int. 2010, 105, 1634-1639.
101. Webb, D.J.; Freestone, S.; Allen, M.J.; Muirhead, G.J. Sildenafil citrate and blood-pressure-lowering drugs: Results of drug interaction studies with an organic nitrate and a calcium antagonist. Am. J. Cardiol. 1999, 83, 21-28.
102. Wright, P.J. Comparison of phosphodiesterase type 5 (PDE5) inhibitors. Int. J. Clin. Pract. 2006, 60, 967-975.
103. Cordeiro, M.N.; Diniz, C.R.; Valentim, A.C.; von Eickstedt, V.R.D.; Gilroy, J.; Richardson, M. The purification and amino acid sequences of four Tx2 neurotoxins from the venom of the Brazilian 'armed' spider Phoneutria nigriventer (Keys). FEBS Lett. 1992, 310, 153-156.
104. Matavel, A.; Fleury, C.; Oliveira, L.C.; Molina, F.; de Lima, M.E.; Cruz, J.S.; Cordeiro, M.N.; Richardson, M.; Ramos, C.H.; Beirao, P.S. Structure and activity analysis of two spider toxins that alter sodium channel inactivation kinetics. Biochemistry 2009, 48, 3078-3088.
105. Nunes, K.P.; Costa-Goncalves, A.; Lanza, L.F.; Cortes, S.F.; Cordeiro, M.N.; Richardson, M.; Pimenta, A.M.; Webb, R.C.; Leite, R.; De Lima, M.E. Tx2-6 toxin of the Phoneutria nigriventer spider potentiates rat erectile function. Toxicon 2008, 51, 1197-1206.
106. Andrade, E.; Villanova, F.; Borra, P.; Leite, K.; Troncone, L.; Cortez, I.; Messina, L.; Paranhos, M.; Claro, J.; Srougi, M. Penile erection induced in vivo by a purified toxin from the Brazilian spider Phoneutria nigriventer. BJU Int. 2008, 102, 835-837.
107. Platnick, N.I. Advances in Spider Taxonomy, 1992-1995: With Redescriptions 1940-1980; New York Entomological Society & The American Museum of Natural History: New York, NY, USA, 1997.
108. Bi, P.; Whitby, M.; Walker, S.; Parton, K.A. Trends in mortality rates for infectious and parasitic diseases in Australia: 1907-1997. Intern. Med. J. 2003, 33, 152-162.
109. Alanis, A.J. Resistance to antibiotics: Are we in the post-antibiotic era? Arch Med. Res. 2005, 36, 697-705.
110. Robbel, L.; Marahiel, M.A. Daptomycin, a bacterial lipopeptide synthesized by a nonribosomal machinery. J. Biol. Chem. 2010, 285, 27501-27508.
111. Vooturi, S.K.; Firestine, S.M. Synthetic membrane-targeted antibiotics. Curr. Med. Chem. 2010, 17, 2292-2300.
112. Yan, L.; Adams, M.E. Lycotoxins, antimicrobial peptides from venom of the wolf spider Lycosa carolinensis. J. Biol. Chem. 1998, 273, 2059-2066.
113. Kuhn-Nentwig, L.; Muller, J.; Schaller, J.; Walz, A.; Dathe, M.; Nentwig, W. Cupiennin 1, a new family of highly basic antimicrobial peptides in the venom of the spider Cupiennius salei (Ctenidae). J. Biol. Chem. 2002, 277, 11208-11216.
114. Ballweber, P.; Markl, J.; Burmester, T. Complete hemocyanin subunit sequences of the hunting spider Cupiennius salei: Recent hemocyanin remodeling in entelegyne spiders. J. Biol. Chem. 2002, 277, 14451-14457.
115. Kuhn-Nentwig, L. Antimicrobial and cytolytic peptides of venomous arthropods. Cell. Mol. Life Sci. 2003, 60, 2651-2668.
116. Nomura, K.; Corzo, G. The effect of binding of spider-derived antimicrobial peptides, oxyopinins, on lipid membranes. Biochim. Biophys. Acta 2006, 1758, 1475-1482.
117. Pukala, T.L.; Boland, M.P.; Gehman, J.D.; Kuhn-Nentwig, L.; Separovic, F.; Bowie, J.H. Solution structure and interaction of cupiennin 1a, a spider venom peptide, with phospholipid bilayers. Biochemistry 2007, 46, 3576-3585.
118. Dubovskii, P.; Volynsky, P.E.; Polyansky, A.A.; Karpunin, D.V.; Chupin, V.V.; Efremov, R.G.; Arseniev, A.S. Three-dimensional structure/hydrophobicity of latarcins specifies their mode of membrane activity. Biochemistry 2008, 47, 3525-3233.
119. Vorontsova, O.V.; Egorova, N.S.; Arseniev, A.S.; Feofanov, A.V. Haemolytic and cytotoxic action of latarcin Ltc2a. Biochimie 2010, doi:10.1016/j.biochi.2010.1009.1016.
120. Corzo, G.; Villegas, E.; Gomez-Lagunas, F.; Possani, L.D.; Belokoneva, O.S.; Nakajima, T. Oxyopinins, large amphipathic peptides isolated from the venom of the wolf spider Oxyopes kitabensis with cytolytic properties and positive insecticidal cooperativity with spider neurotoxins. J. Biol. Chem. 2002, 277, 23627-23637.
121. Kuhn-Nentwig, L.; Schaller, J.; Nentwig, W. Biochemistry, toxicology and ecology of the venom of the spider Cupiennius salei (Ctenidae). Toxicon 2004, 43, 543-553.
122. Adão, R.; Seixas, R.; Gomes, P.; Pessoa, J.C.; Bastos, M. Membrane structure and interactions of a short Lycotoxin I analogue. J. Pept. Sci. 2008, 14, 528-534.
123. Henriques, S.T.; Craik, D.J. Cyclotides as templates in drug design. Drug Discov. Today 2010, 15, 57-64.
124. World Health Organization. World Malaria Report 2009; WHO Press: Geneva, Switzerland, 2009.
125. Enayati, A.; Hemingway, J. Malaria management: past, present, and future. Annu. Rev. Entomol. 2010, 55, 569-591.
126. Staines, H.M.; Ellory, J.C.; Chibale, K. The new permeability pathways: targets and selective routes for the development of new antimalarial agents. Comb. Chem. High Throughput Screen 2005, 8, 81-88.
127. Nicholson, G.M.; Graudins, A. Spiders of medical importance in the Asia-Pacific: atracotoxin, latrotoxin and related spider neurotoxins. Clin. Exp. Pharmacol. Physiol. 2002, 29, 785-794.
128. Craik, D.J.; Adams, D.J. Chemical modification of conotoxins to improve stability and activity. ACS Chem. Biol. 2007, 2, 457-468.
129. Vlieghe, P.; Lisowski, V.; Martinez, J.; Khrestchatisky, M. Synthetic therapeutic peptides: science and market. Drug Discov. Today 2010, 15, 40-56.
130. Knauf, M.J.; Bell, D.P.; Hirtzer, P.; Luo, Z.P.; Young, J.D.; Katre, N.V. Relationship of effective molecular-size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers. J. Biol. Chem. 1988, 263, 15064-15070.
131. Pettit, D.K.; Gombotz, W.R. The development of site-specific drug-delivery systems for protein and peptide biopharmaceuticals. Trends Biotechnol. 1998, 16, 343-349.
132. Tedford, H.W.; Fletcher, J.I.; King, G.F. Functional significance of the β-hairpin in the insecticidal neurotoxin ω-atracotoxin-Hv1a. J. Biol. Chem. 2001, 276, 26568-26576.
133. Tedford, H.W.; Gilles, N.; Ménez, A.; Doering, C.J.; Zamponi, G.W.; King, G.F. Scanning mutagenesis of ω-atracotoxin-Hv1a reveals a spatially restricted epitope that confers selective activity against invertebrate calcium channels. J. Biol. Chem. 2004, 279, 44133-44140.
134. Gadek, T.R.; Nicholas, J.B. Small molecule antagonists of proteins. Biochem. Pharmacol. 2003, 65, 1-8.
135. Baell, J.B.; Duggan, P.J.; Lok, Y.P. ω-Conotoxins and approaches to their nonpeptide mimetics. Aust. J. Chem. 2004, 57, 179-185.
136. Harvey, A.J.; Gable, R.W.; Baell, J.B. A three-residue, continuous binding epitope peptidomimetic of ShK toxin as a Kv1.3 inhibitor. Bioorg. Med. Chem. Lett. 2005, 15, 3193-3196.